Remegen Co., Ltd.

This study tests a drug called telitacicept for people with ocular myasthenia gravis, a condition that causes droopy eyelids and double vision. About 120 participants aged 12 to 80 will receive either the drug or a placebo for 24 weeks. The goal is to see if telitacicept improves…

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good organ function may join.

This study compares two drug combinations for people with advanced squamous non-small cell lung cancer who have not had treatment before. About 574 participants will receive either RC148 or tislelizumab, both combined with standard chemotherapy. The goal is to see which combinati…

This study tests whether a combination of three drugs (disitamab vedotin, pertuzumab, and toripalimab) given before surgery can completely eliminate HER2-positive breast cancer in 40 adults. The main goal is to see if no cancer remains in the breast or lymph nodes after treatment…

This study tests a new three-drug combination (disitamab vedotin, trastuzumab, and tislelizumab) against standard chemotherapy plus trastuzumab with or without pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that has high levels of HER2. The goa…